HMG-coenzyme A reductase inhibition, type 2 diabetes,and bodyweight: evidence from genetic analysis and randomised trials

Lancet

8 October Oct 2014 11 years ago
  • Daniel I Swerdlow, David Preiss, Karoline B Kuchenbaecker, Michael V Holmes, Jorgen E L Engmann, Tina Shah, Reecha Sofat, et al, Damiano Baldassarre, Bengt Sennblad, Elena Tremoli, Ulf de Faire, Fabrizio Veglia, Ian Ford, J Wouter Jukema, et al.
QR Code
Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target.  The increased risk of type 2 diabetes noted with statins is at least partially explained by HMGCR inhibition.